Cidara Therapeutics Inc Stock
-
Your prediction
Cidara Therapeutics Inc Stock
Pros and Cons of Cidara Therapeutics Inc in the next few years
Pros
Cons
Performance of Cidara Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 0.000% | -4.950% | -0.518% | 124.561% | 15.663% | -11.111% | -60.615% |
| Northwest Biotherapeutics Inc. | 0.000% | -8.889% | -3.529% | -39.259% | -20.388% | -65.546% | -85.357% |
| Celldex Therapeutics | -0.900% | 3.160% | 12.227% | 75.183% | 30.591% | -11.871% | 30.948% |
Comments
News
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
According to a November 14, 2025 SEC filing, HighVista Strategies LLC initiated a new stake in Cidara Therapeutics (NASDAQ:CDTX), acquiring 70,904 shares worth $6.79 million as of September 30
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this



